EAU 2012 - Injecting DIGNITY into your neurogenic detrusor overactivity (NDO) patient treatment paradigm: The role of botulinum toxin type A - Session Highlights

PARIS, FRANCE (UroToday.com) - The symposium was chaired by Prof. Emmanuel Chartier-Kastler, who, along with his colleagues, has over 10 years experience in the use of Botox treatment for patients with MS and spinal cord injuries.

They shared their personal experiences as well as new findings of the Phase III study called DIGNITY: Double-blind investigation of purified neurotoxin complex for neurogenic detrusor overactivity. Results in this population showed that Botox significantly reduced UI and improved UDS findings and was found to be superior to placebo.

The speakers provided case studies, shared their methodology for performing injections, and cited some common complications - including urinary retention. It was interesting to note that in several MS patient presentations, a decrease in recurrent UTIs was a finding.

Symposium sponsored by Allergan.

 

Presented at the 13th International European Association of Urology Nurses (EAUN) Meeting - February 24 - 28, 2012 - Le Palais des Congrès de Paris, Paris, France

 


 

The opinions expressed in this article are those of the UroToday.com Medical Editor and do not necessarily reflect the viewpoints of the European Association of Urology Nurses (EAUN)

 

View EAU 2012 Annual Meeting Coverage

email news signup